Keystone symposia – Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics

Keystone symposia – Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics

 

Biognosys is proud to present the highlights of a recent study in which we describe the potentialities of limited proteolysis for proteomics analysis. The oral presentation, “Limited proteolysis as a proteomics tool for target deconvolution and mechanistic insights – a test case,” will be held by our Scientific Director of Discovery Proteomics, Nigel Beaton, on May 25th.

 

Contact

    Close banner

    New: Spectronaut® 19

    Unlock Your Data's True Story

    New: Spectronaut® 19

    Unlock Your Data's True Story

    Learn More